ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis
USA - NASDAQ:ACAD - US0042251084 - Common Stock
22.57 USD
+0.92 (+4.25%)
22.57 USD
0 (0%)
Taking everything into account, ACAD scores 6 out of 10 in our fundamental rating. ACAD was compared to 534 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
ACAD had positive earnings in the past year.
ACAD had a positive operating cash flow in the past year.
ACAD had negative earnings in 4 of the past 5 years.
In multiple years ACAD reported negative operating cash flow during the last 5 years.
1.2 Ratios
ACAD has a Return On Assets of 18.13%. This is amongst the best in the industry. ACAD outperforms 96.44% of its industry peers.
Looking at the Return On Equity, with a value of 27.01%, ACAD belongs to the top of the industry, outperforming 97.19% of the companies in the same industry.
ACAD has a better Return On Invested Capital (8.85%) than 94.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROIC | 8.85% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ACAD has a Profit Margin of 21.80%. This is amongst the best in the industry. ACAD outperforms 94.94% of its industry peers.
The Operating Margin of ACAD (8.86%) is better than 91.76% of its industry peers.
ACAD's Gross Margin of 91.97% is amongst the best of the industry. ACAD outperforms 92.51% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ACAD is still creating some value.
Compared to 1 year ago, ACAD has more shares outstanding
ACAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ACAD has an Altman-Z score of 4.66. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ACAD (4.66) is better than 74.53% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.66 |
ROIC/WACC1.01
WACC8.75%
2.3 Liquidity
ACAD has a Current Ratio of 2.91. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ACAD (2.91) is worse than 64.79% of its industry peers.
A Quick Ratio of 2.83 indicates that ACAD has no problem at all paying its short term obligations.
The Quick ratio of ACAD (2.83) is worse than 64.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 |
3. Growth
3.1 Past
The earnings per share for ACAD have decreased strongly by -34.62% in the last year.
Looking at the last year, ACAD shows a very strong growth in Revenue. The Revenue has grown by 31.85%.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 23.08% on average per year.
EPS 1Y (TTM)-34.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)31.85%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%11.27%
3.2 Future
ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.38% yearly.
ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.84% yearly.
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ACAD is valuated quite expensively with a Price/Earnings ratio of 44.25.
92.13% of the companies in the same industry are more expensive than ACAD, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 25.83. ACAD is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 25.79, which means the current valuation is very expensive for ACAD.
Based on the Price/Forward Earnings ratio, ACAD is valued cheaper than 91.57% of the companies in the same industry.
ACAD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 32.68, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.25 | ||
| Fwd PE | 25.79 |
4.2 Price Multiples
93.26% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
92.88% of the companies in the same industry are more expensive than ACAD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.1 | ||
| EV/EBITDA | 22.91 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ACAD does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ACAD may justify a higher PE ratio.
A more expensive valuation may be justified as ACAD's earnings are expected to grow with 37.81% in the coming years.
PEG (NY)2.05
PEG (5Y)N/A
EPS Next 2Y35.04%
EPS Next 3Y37.81%
5. Dividend
5.1 Amount
No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
22.57
+0.92 (+4.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners102.78%
Inst Owner Change-0.19%
Ins Owners0.3%
Ins Owner Change1.1%
Market Cap3.81B
Revenue(TTM)957.80M
Net Income(TTM)222.16M
Analysts77.04
Price Target29.74 (31.77%)
Short Float %5.22%
Short Ratio4.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.63%
Min EPS beat(2)-3.19%
Max EPS beat(2)14.46%
EPS beat(4)2
Avg EPS beat(4)-13.96%
Min EPS beat(4)-109.07%
Max EPS beat(4)41.97%
EPS beat(8)5
Avg EPS beat(8)7.72%
EPS beat(12)7
Avg EPS beat(12)13.12%
EPS beat(16)10
Avg EPS beat(16)17.21%
Revenue beat(2)1
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.93%
Max Revenue beat(2)0.08%
Revenue beat(4)1
Avg Revenue beat(4)-2.63%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)4
Avg Revenue beat(8)-0.28%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)7
Avg Revenue beat(16)-1.31%
PT rev (1m)-3.17%
PT rev (3m)2.71%
EPS NQ rev (1m)-2.1%
EPS NQ rev (3m)7.25%
EPS NY rev (1m)3.26%
EPS NY rev (3m)10.61%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)0.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 44.25 | ||
| Fwd PE | 25.79 | ||
| P/S | 3.74 | ||
| P/FCF | 43.1 | ||
| P/OCF | 20.25 | ||
| P/B | 4.63 | ||
| P/tB | 5.38 | ||
| EV/EBITDA | 22.91 |
EPS(TTM)0.51
EY2.26%
EPS(NY)0.88
Fwd EY3.88%
FCF(TTM)0.52
FCFY2.32%
OCF(TTM)1.11
OCFY4.94%
SpS6.04
BVpS4.87
TBVpS4.2
PEG (NY)2.05
PEG (5Y)N/A
Graham Number7.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.13% | ||
| ROE | 27.01% | ||
| ROCE | 10.08% | ||
| ROIC | 8.85% | ||
| ROICexc | 59.33% | ||
| ROICexgc | 412.73% | ||
| OM | 8.86% | ||
| PM (TTM) | 21.8% | ||
| GM | 91.97% | ||
| FCFM | 8.67% |
ROA(3y)-8.62%
ROA(5y)-17.17%
ROE(3y)-12.41%
ROE(5y)-22.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.7%
GM growth 5Y-0.59%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 729.13% | ||
| Cap/Sales | 9.78% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 180.83% | ||
| Profit Quality | 39.76% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.83 | ||
| Altman-Z | 4.66 |
F-Score6
WACC8.75%
ROIC/WACC1.01
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)1.86%
Cap/Sales(5y)1.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-34.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y21.55%
EPS Next 2Y35.04%
EPS Next 3Y37.81%
EPS Next 5Y39.38%
Revenue 1Y (TTM)31.85%
Revenue growth 3Y25.54%
Revenue growth 5Y23.08%
Sales Q2Q%11.27%
Revenue Next Year10.06%
Revenue Next 2Y10.93%
Revenue Next 3Y10.69%
Revenue Next 5Y9.84%
EBIT growth 1Y307.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.53%
EBIT Next 3Y32.73%
EBIT Next 5Y43.57%
FCF growth 1Y218.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y647.78%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the ChartMill fundamental rating of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to ACAD.
Can you provide the valuation status for ACADIA PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What is the earnings growth outlook for ACADIA PHARMACEUTICALS INC?
The Earnings per Share (EPS) of ACADIA PHARMACEUTICALS INC (ACAD) is expected to grow by 21.55% in the next year.